Transcriptomics close to my heart:advanced models &amp; methods for toxicogenomics research illustrated by anthracycline-induced cardiotoxicity by Verheijen, Marcha
  
 
Transcriptomics close to my heart
Citation for published version (APA):
Verheijen, M. (2019). Transcriptomics close to my heart: advanced models & methods for toxicogenomics
research illustrated by anthracycline-induced cardiotoxicity. Maastricht: ProefschriftMaken Maastricht.
https://doi.org/10.26481/dis.20190517mv
Document status and date:
Published: 01/01/2019
DOI:
10.26481/dis.20190517mv
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
    145    
Chapter 6 
Summary and General Discussion 
 
   Chapter 6: Summary & Discussion    
   146     
C
h
ap
ter 
     Current drug development and safety testing procedures are time consuming, 
expensive and not able to detect all human drug-induced toxicity risks, with occasional 
severe adverse drug reactions as a consequence. The adverse drug reactions also rank 
high as cause for disease or death
[1]
. In search for methods to improve in vitro 
toxicological drug safety assessments, we adopted an experimental design better 
reflecting the human in vivo conditions and investigated possibilities to improve 
toxicogenomics data analysis. Here, we predominantly focused on post-transcriptional 
mechanisms. 
     As an example toxicant, we mainly used doxorubicin (DOX), but to some extent also 
epirubicin (EPI) and idarubicin (IDA) were studied in vitro in the human cardiac 3D 
microtissue model. These chemotherapeutic agents belong to the group of 
anthracyclines (ANTs) and are known to dose-dependently induce cardiotoxicity
[2,3]
. 
The occurrence of cardiotoxicity is difficult to predict, because it can manifest at any 
stage during the treatment (reversible acute cardiotoxicity) or even months or years 
after the treatment has ended (irreversible delayed chronic cardiotoxicity) while the 
involved molecular mechanisms are only partially understood
[2-6]
. 
Experimental design  
     Within toxicology, the experimental design typical includes the use of a solvent like 
Dimethyl sulfoxide (DMSO) in order make a stable stock solution of the investigated 
compound. However, in the 1960s DMSO was researched for medical use due to its 
biological effects. During the clinical trials, high doses of DMSO induced extreme 
toxicities, especially to the eyes, though. Because the effects of DMSO differ 
depending on dose and route of administration, the FDA classified DMSO in the safest 
category with low toxic potential at levels normally accepted in pharmaceuticals
[7]
. This 
made the wide use of DMSO possible. 
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     Though it often assumed that effects of DMSO are negligible
[8-10]
, we evaluated the 
impact of 0.1% DMSO exposure using sensitive high-throughput techniques (Chapter 
2). We did this for the cardiac microtissue model relevant for this thesis, but also for 
the hepatic microtissue model used by other partners of the HeCaToS project.  
     DMSO effects on cellular processes were analyzed using full transcriptome data 
supplemented with proteomics data. More than 2000 differentially expressed genes 
(DEGs, FDR <0.05) and 650 differentially expressed proteins (DEPs, FDR <0.05) were 
detected in both tissue types, of which more than half were downregulated. Pathway 
analysis indicated that similar biological processes were affected in both cell types, 
indicating consistent cross-organ actions of DMSO. 
     Observed DMSO-induced changes in cellular processes included changes in 
mitochondrial pathways linked to ROS production and cellular ATP generation. 
Functional measurements of microtissue ATP content for the hepatic model revealed a 
small initial decrease (36% decrease in the first 72h), after which ATP content slowly 
recovered to baseline level. However, a steep decrease over time (87% decrease after 
2 weeks of exposure) was observed for cardiac microtissues. This decrease in ATP 
production may impact toxicological research because changes in the amount of free 
energy in the cell influences the capability of the cell to deal with induced stresses, 
thereby potentially leading to erroneous interpretation of results from in vitro assays. 
The DMSO-induced ATP decrease is of even more relevance for the field of assisted 
reproductive technology, in which DMSO is used for cryopreservation of oocytes and 
embryos for IVF treatments. Here the ATP content is used as a predictor of embryo 
viability. Decreased ATP levels, especially in the cleavage-stage, can induce 
downstream effects that may disrupt cellular function, implantation ability and fetal 
development
[11,12]
. 
     While observed tissue-specific differences may be due to tissue type, they may also 
result from a fundamental difference in the cell model, because the cardiac model 
contains iPSC-derived human cardiomyocytes that are still maturing, while the hepatic  
   Chapter 6: Summary & Discussion    
   148     
C
h
ap
ter 
model contains mature human hepatocytes. Expanding our research to the epigenetic 
landscape also revealed tissue-specific effects of DMSO. Analysis of miRNAs indicated a 
complete deregulation of cardiac miRNA biogenesis and miRNA content. Though 
changes in hepatic miRNA biogenesis were minimal, still 18% of detected miRNAs were 
significantly changed by DMSO exposure.   
     Furthermore, we showed, for the first time, the influence of DMSO on the DNA 
methylation patterns of human cells in vitro. Whole genome methylation profiling by 
MeDIP-seq revealed 66,178 differentially methylated regions (DMRs; q-value <0.05) in 
cardiac microtissues with 71% hypermethylated, while in hepatic microtissues, no 
DMRs passed correction for multiple testing. While repetitive sequences appeared 
preferentially affected, findings also suggested a global deregulation of DNA 
methylation mechanisms leading to genome-wide changes. It is uncertain if exposed 
cells can recover from temporary DMSO exposures. While methylation changes have 
an adaptive nature, they may also be persistent and even heritable by the offspring to 
induce transgenerational effects
[13-17]
. This may pose a threat, especially for 
cryopreserved oocytes and embryos for IVF treatment which are exposed to high 
concentrations of DMSO during the periconceptional period (before conception until 
early pregnancy), when epigenetic reprogramming is taking place. 
 
     Overall, the extreme changes in microRNAs and alterations in the epigenetic 
landscape indicated that DMSO is not inert. Therefore, use of DMSO should be avoided 
where possible. However, for the time being, DMSO is indispensable within 
biotechnological applications, including toxicological research. To reduce the impact of 
DMSO, concentrations should be kept as low as possible. 
 
     A decrease in DMSO concentration was incorporated within the innovative in vitro 
experimental design which we validated in Chapter 3. Next to using the human cardiac 
microtissue model, which better resembles the human heart in vivo due to its 3D 
spheroid structure and the co-culturing of both cardiomyocytes and fibroblasts, we 
also included physiologically based pharmacokinetic (PBPK) modelling in order to  
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achieve a repetitive dosing profile which resembled the in vivo drug concentrations in 
the human heart. The highest exposure was 0.06% DMSO for 2 hours per day, 
continuing with 0.006% for 6 hours and ending with 0.0025% for 16 hours. 
     This experimental design was validated by assessing whether our model was able to 
retrieve the known mechanisms of DOX through pathway analysis and in depth 
analysis of mitochondrial dysfunction. While DOX mechanisms of action are not fully 
understood, it is generally accepted that the main mode of action is related to killing 
dividing cells. DOX has been found to 1) intercalate into DNA, 2) target DNA 
topoisomerases, and 3) generate reactive oxygen species (ROS)
[18-20]
. The first two 
processes inhibit unwinding of DNA, DNA replication, RNA transcription and protein 
biosynthesis. As a result, proliferation of dividing cells is also inhibited
[21,22]
. This is 
thought to be the efficacy of the anti-cancer effects of DOX, while ROS generation is 
mainly ascribed to toxic effects
[23]
. The induced oxidative stress may damage cells and 
cause cell death
[19,24]
. Other detrimental actions of DOX can be related to death of non-
cancer cells or to decreased cardiomyocyte functioning, which may partly result from 
mitochondrial dysfunction causing an imbalance in cellular energetics
[25]
. The 
detrimental actions of DOX, known to occur in vivo, can thus be summarized into 3 
toxicity processes: cardiomyocyte dysfunction, mitochondrial dysfunction and cell 
death. We were able to successfully detect biological changes in these three processes 
in our in vitro model by applying next-generation total RNA-sequencing to ribo-
depleted RNA samples.  
     Pathway analysis of differentially expressed genes (FDR<0.05) identified toxicity of 
DOX by gene expression changes in the pathways of “striated muscle contraction” (= 
cardiac dysfunction), “TCA cycle & respiratory electron transport” (= mitochondrial 
dysfunction) and “cellular senescence” (= cell death). A central link between the 
toxicity pathways was the “formation of ATP by chemiosmotic coupling”. 
Mitochondrial gene expression changes correlated with ATP measurements, in which 
the therapeutic dose displayed a relatively stable ATP content, while ATP content 
during toxic exposure decreased drastically over time. A more detailed analysis of 
mitochondrial dysfunction revealed gene expression changes in the process of ROS 
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detoxification, which confirms DOX-induced ROS generation in our in vitro model. 
Furthermore, effects of DOX on the electron transport chain (ETC) and ATP production 
was observed, with upregulations across time for the therapeutic exposure and a 
majority of downregulations during the second half of toxic exposures.  
     Many studies on DOX effects have been performed with high doses in order to 
observe toxic effects. However, our in vitro model clearly demonstrated a dose-
dependent effect of DOX exposure, highlighting the importance of applying 
physiologically relevant dosing profiles during toxicological research. Exposure to the 
toxic dosing profile reflected processes of acute cardiotoxicity, as observed though a 
decrease in ATP content and an increase in cell death. On the other hand, therapeutic 
doses reflected processes underlying the phenotype of delayed chronic cardiac toxicity. 
The increase in gene expression of mitochondrial and ETC genes was necessary in 
order to maintain a stable cellular ATP content, indicating an adaptation response. 
Because genes involved in striated muscle contraction were already showing 
decreased expression levels, this adaptation response may not be sufficient for 
maintaining cardiac function. Cumulative toxicity may therefore surpasses the point to 
which the organ can adapt, thereafter resulting in a delayed phenotype of heart failure, 
as is observed in patients with chronic cardiotoxicity after DOX treatment
[25,26]
. These 
same dose-dependent effects were also observed for the other ANTs (EPI and IDA) 
analysed in Chapter 4. 
Advanced transcriptomics analysis  
     In Chapter 4, we went beyond conventional gene-expression analysis by 
investigation of ANT-induced changes in alternative splicing. Through alternative 
splicing, a single gene encodes multiple variants of RNA transcripts with distinct 
functions
[27]
. This greatly increases the diversity of the transcriptome
[28,29]
, which can 
be measured using RNA-sequencing technology. It is estimated that 92-94% of human 
genes are subjected to alternative splicing
[27]
. During gene expression analysis, the sum 
of these transcripts is assessed. However, due to differences in biological function of 
alternatively spliced transcripts, not only changes in gene expression, but also changes 
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in ratios of expressed transcripts (differential transcript usage; DTU) can result in a 
distinct phenotype
[29,30]
. Therefore it is important to make use of technological 
advances of recent years to analyze DTU for elucidating toxicological mechanisms.  
     ANT-induced changes in alternative splicing were investigated for sarcomeric genes. 
The sarcomere is the cellular compartment facilitating contraction and is therefore 
highly important for heart function and cardiotoxic effects. The most interesting ANT-
induced changes were observed for the titin gene (TTN) which is essential for 
maintaining the structure of the sarcomere because it forms the base for the assembly 
of the contractile machinery. During relaxation, its protein product unfolds and refolds 
during contraction. Furthermore, the in vitro observed ANT-induced changes could 
also be detected in human biopsies of heart failure patients with or without prior ANT 
therapy, confirming the clinical relevance of these observed effects. While the 
expression of the titin gene (TTN) differed between the ANTs, ranging from no 
significant changes (IDA) to downregulated at every time point (EPI), DTU analysis 
identified the most significant change in transcript usage for the TTN-206 transcript in 
all three ANTs (FDR: 6.96∙10
-32
, 2.04∙10
-31
 & 1.38057∙10
-39
 for DOX, EPI & IDA, resp.). 
The decrease in TTN-206 transcript usage was correlated in vivo with increased left 
ventricular (LV) mass index (p= 0.002), decreased LVEF (p=0.018) and was the only 
transcript close to significant (P=0.07) when comparing dilated vs undilated 
morphologies. The switch form TTN-206 (encoding H7C1P9, 962aa) to TTN-212 
(encoding Q8WZ42, 26.926aa) changes the expression of a truncated titin protein 
variant. These truncated variants have the ability to impact the structural organization 
of sarcomeres and to disturb regulation of sarcomeric passive force generation and 
reduce the efficiency of contraction
[31-33]
.  
     To summarize, while changes in overall TTN gene expression were unable to identify 
interesting ANT-induced effects, analysis of DTUs identified the decrease of TTN-206 
which can be a highly promising as a biomarker for early detection of ANT-induced 
cardiotoxicity because it correlated with increased LV mass index, decreased LVEF and  
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can possibly distinguish between dilated and unaffected morphologies. This shows the 
added value of biological information to be gained from DTU analysis as compared to 
standard gene expression analysis.  
     Next to analysis of alternative splicing, other post-transcriptional mechanisms can 
also be investigated using RNA sequencing technologies. In Chapter 5, we focused on 
the incorporation of microRNA (miRNA) and circular RNA (circRNA) regulatory actions 
in transcriptomics analysis. MicroRNAs, small non-coding RNAs of approximately 22 
nucleotides
[1,34]
, can bind through complementary base pairing to regions within the 
3’UTR of the mRNA (known as seed regions). This interaction can inhibit the translation 
of a mRNA. Furthermore, circRNAs, which are closed continuous loops without 5’caps 
or 3’tails which are generated through head-to-tail mRNA splicing
[35,36]
, can also bind 
miRNAs. Because these circRNAs are highly stable and resistant against degradation, 
the miRNAs are captured and their inhibitory effect on translation is prevented
[37]
.   
     Because regulatory mechanisms acting on translation are proposed to be the main 
cause for the notoriously poor correlation between the transcriptome and the 
proteome
[38-40]
, we postulate that the assessment of these post-transcriptional 
mechanisms is important. On the short term, this will increase our understanding of 
biological and toxicological processes. On the long term, we might be able to 
incorporate the obtained knowledge to design an in silico prediction system to 
estimate the amount of translatable mRNAs, thereby obtaining a highly detailed 
genome-wide measurement with a biological relevance similar to proteomics data 
which can be used for toxicological assessments. We therefore designed a scoring 
system for genome-wide estimation of post-transcriptional miRNA and circRNAs 
interactions on mRNA translation. This scoring system estimates the fraction of 
miRNAs which are able to inhibit mRNAs translation because they are not captured by 
circRNAs. We labelled the obtained score as the miRNA-induced inhibition of 
translation (MIT) score, of which the calculation was based on the expression values 
and predicted interactions of mRNA, miRNA and circRNA.  
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     Using the cardiac microtissues exposed to the therapeutic DOX dosing profile, we 
conducted a pilot study to validate our scoring system. Because a MIT score was 
obtained for every miRNA able to influence a target transcript, tens to hundreds of MIT 
scores were obtained per transcript. For interpretation of these MIT scores, we 
assessed the use of 1) MIT
Mean
, which reflected the average inhibition efficiency of all 
miRNAs influencing a transcript, and 2) MIT
Max
, which reflected the maximum MIT 
score because we envisioned that this miRNA was responsible for the inhibitory effect 
while effects of other miRNAs might be negligible in comparison. To determine which 
of these parameters best disclosed relevant biological processes within the cell, we 
first estimated the amount of translatable read count (TRC) using the MIT
Mean
 and the 
MIT
Max
. Thereafter, we assessed whether the correlation between the proteome and 
the TRCs was improved compared to the correlation of the proteome with RNA read 
counts. We found improvements of correlation for 47.5% of cases using TRC
Mean
 values 
and 45% of cases using TRC
Max
 values. While the absolute improvement of TRC
Mean
 was 
very low (∆r<0.05), TRC
Max
 indicated more relevant improvements of correlation (0.05 
< ∆r < 0.886). Furthermore, when plotting the protein-abundances and TRC
Max
 values, 
the obtained graphs were visually very similar, which was not the case for RNA read 
counts. This demonstrated the ability of the MIT
Max
 and the TRC
Max
 to reflect 
biologically relevant translation inhibition processes.  
     Using the scoring system, we identified significant DOX-induced changes in miRNA-
circRNA regulation in 60% of investigated transcripts (n=480). Because 63% of the 
significantly changes comprised an increase in MIT
Max
 score, we concluded that DOX 
was capable of strongly decreasing RNA translation through changes in regulatory 
miRNA-circRNA processes. Overall, the ability of the scoring system to identify changes 
in miRNA-circRNA regulatory systems as confirmed by the proteomics data, highlights 
the importance for assessment of post-transcriptional mechanisms, not only in 
toxicogenomics research but in genomics research in general. 
   Chapter 6: Summary & Discussion    
   154     
C
h
ap
ter 
Conclusions and Future perspectives 
     We hypothesized that the use of an experimental design better reflecting the 
human in vivo conditions combined with analysis of post-transcriptional mechanisms 
would aid the evolution of toxicogenomics research in order to improve drug safety 
assessments in the future. Using the ANTs as a case study, we indeed showed the 
possibilities of improving the experimental design to relate more closely to the in vivo 
situation and displayed the vast amount of information gained from studying post-
transcriptional mechanisms. 
     In Chapter 5 we showed the importance for quantifying post-transcriptional effects 
of miRNA-circRNA regulation of translation through the use of a scoring system to 
identify biologically relevant toxicant-changes which may play a role in toxicity.  
     Because the scoring system is currently restricted to the estimation of miRNAs and 
circRNAs regulatory effects, expansion to include other post-transcriptional 
mechanisms (such as alternative splicing) may be considered. Furthermore, the current 
scoring system may benefit from optimization through the use of more recently 
developed tools for circRNA prediction approaches (e.g. CIRCexplorer2
[41]
 or CIRI2
[42]
) 
and possibly the use of an alternative parameter for optimal interpretation. While our 
pilot study indicated that the miRNA with the maximum MIT score was better suited 
for biological interpretation of translation inhibition, compared to the average of the 
obtained MIT scores, this means that effects of other miRNAs are neglected. 
Alternatively, the scoring system could be adapted to return the combined effects of 
all miRNAs affecting a target transcript. Another possibility would be to use a machine 
learning approach which trains, validates and tests the scoring system in order to 
improve the precision of the prediction. However, most important would be to 
validate the scoring system using a multitude of compounds for which the results can 
be validated using literature or laboratory experiments. 
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     In Chapter 4, analysis of DTU revealed highly significant changes for the titin gene, 
which were not detected using observed standard gene expression analysis. This 
clearly demonstrated the added value for analyzing RNA splicing effects after exposure 
to a toxicant. 
     Human patient biopsies were used to validate in vitro DTU observations in vivo. 
Because of the low number of biopsies available from ANT treated patients (n=7) and 
the observed heterogeneity of these human biopsies, the research would clearly 
benefit from additional validation efforts using more patient samples. Recently we 
obtained a new batch of human cardiac biopsies which could be included in the 
analysis, resulting in a total of 15 biopsies available from ANT treated patients. 
Furthermore, because the biological function of many of transcript isoforms has not 
been determined, we could only speculate about the biological impact of changes 
observed for these transcripts. Loss-of-function assays (e.g. RNAi screening
[43]
) to 
elucidate the functions of transcript variants are necessary (for both coding and non-
coding transcripts) in order to draw reliable biological conclusions. Finally, our cell 
model contains induced pluripotent stem cells (iPSC)-derived cardiomyocytes which 
are known to acquire genetic variation during reprogramming of the cells, implying 
that batches of microtissues were not identical between the different ANT-exposures. 
Therefore, observed DTU in vitro could also have been due to different single 
nucleotide polymorphisms (SNPs) existing between the batches. Therefore, for the 
presented study, we regarded findings as reliable when detected in both in vitro 
microtissues and in vivo biopsies. For future research on DTU using iPSC-derived cell 
models, a multitude of iPSC batches should be exposed to obtain results across a 
variety of genomic backgrounds and the iPSC batches should be identical between 
exposure studies in order to facilitate comparability.   
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     In Chapter 3, our in vitro model including 3D microtissues and PBPK-based exposure 
profiles revealed a clear difference in activated biological mechanisms between the 
therapeutic and the toxic ANT exposure profile. This clearly indicates that future 
toxicological research should be performed at doses to which the human population 
can be exposed in order to obtain relevant safety assessments. 
     It should be taken into account that here only the effect of DOX on heart 
microtissues was investigated. For developing a predictive model for repeated dose 
heart toxicity, future research should thus be performed using additional toxicants and 
other tissue types (e.g. liver microtissues). Furthermore, next to 3D microtissues, also 
other in vitro systems mimicking the in vivo environment have been developed (e.g. 
organoids) which could also be of interest for toxicological research. Similar to 
microtissues, organoids are in vitro 3D models gained from pluripotent stem cells 
(either embryonic or induced) or primary tissue
[44]
. Organoids are physiologically closer 
to in vivo then microtissues because they contain more cell types, are larger in size and 
are capable of self-renewal. Because of this self-renewal, they can also be cultured for 
extended time. These features would be beneficial for toxicity assessment. However, 
culturing techniques for organoids are much more complex compared to culturing of 
microtissues, which could hamper large scale toxicity assessments.  
     Chapter 2 revealed that, contradictory to general assumptions, DMSO is not an inert 
solvent. Even at the commonly used “low” concentration of 0.1%, DMSO was able to 
induce extreme changes in the epigenetic landscape. With the development of more 
sensitive analysis techniques, the doses used for toxicological research are also 
decreasing. In Chapter 3 we highlighted the need for investigating relevant doses. For 
DOX, the highest used doses were 0.22μM and 0.65μM for the therapeutic and toxic 
ANT exposure respectively. Compared to these low doses, these extremely high 
concentration of 14.1 mM DMSO (=0.1%) could induce changes which may result in 
erroneous conclusions gained from in vitro assays, such as false negative drug toxicity 
conclusions. Which brings us to a final but very strong message: In the future, avoid 
using DMSO where possible! 
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     Overall, this thesis demonstrates the benefits of using advanced models & methods 
for toxicogenomics research. We introduced an advanced experimental design better 
reflecting the human in vivo conditions through incorporation of a 3D cell culture 
model, exposure to physiologically relevant concentrations and a reduction of the 
DMSO concentration. Furthermore, we highlighted the added value of advanced 
toxicogenomics data analysis through assessment of post-transcriptional mechanisms 
such as alternative splicing and translational regulation by miRNAs and circRNAs. 
Application of this model and these methods could improve future in vitro toxicological 
drug safety assessments.  
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